Navigation Links
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
Date:3/22/2011

TUESDAY, March 22 (HealthDay News) -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.

Italian researchers collected data on 832 patients who were taking Gleevec (imatinib) for up to eight years and found that 20 patients died during the follow-up period. That death rate of 4.8 percent, however, is similar to what would be expected in the general population.

Only six deaths were related to chronic myeloid leukemia (CML), the researchers noted.

Serious adverse events such as cardiovascular and digestive problems were reported in 139 patents, but only 27 cases (19 percent) were considered to be related to Gleevec, according to the study.

Other adverse events frequently connected to Gleevec included muscle cramps, weakness, edema, skin fragility, diarrhea, and tendon or ligament lesions. Nineteen patients (2.3 percent) stopped taking Gleevec due to side effects, with half switching to another drug.

Patients taking Gleevec "frequently suffer from side effects that are non-serious but can nonetheless reduce their quality of life," the researchers wrote.

The study authors disclosed no conflicts of interest, noting that their independence from pharmaceutical interests was a major strength of the study.

The researchers also noted the "importance of a good patient-provider relationship, in which side effects are easily communicated and addressed to reduce/avoid non-compliance."

In an accompanying editorial, Dr. B. Douglas Smith of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, noted "the astounding effect [imatinib] has had on the clinical course of this disease."

However, he wrote that many patients in the study had been treated first with interferon, which may have been a factor in their remissions. For this reason, he concluded, "a careful analysis of the two groups" -- patients who had taken interferon and those who had not -- "might help shed light on this issue."

The study appears online March 22 in the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about chronic myeloid leukemia.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, March 22, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Less Is More With Acute Myeloid Leukemia Drug
2. When leukemia returns, gene that mediates response to key drug often mutated
3. A small subset of normal white blood cells gives rise to a rare leukemia, study shows
4. Scientists bioengineer a protein to fight leukemia
5. Southampton scientists begin patient trials of new leukemia cancer vaccine
6. Discovery of a gene associated with a leukemia mostly affecting children
7. MicroRNA-TP53 circuit connected to chronic lymphocytic leukemia
8. Gene Activity May Affect Acute Myeloid Leukemia Outcome
9. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
10. Researchers make critical leukemia stem cell discovery
11. New therapies and gene target advance the treatment and understanding of hard-to-treat leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Calif. (PRWEB) , ... March 24, 2017 , ... ... raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... instant demand for the product – with nearly 2,000 consumers (and counting) already ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
(Date:3/27/2017)... HAMILTON, N.J. , March 27, 2017 ... company and leading in vivo pharmacology contract ... Solar Farm adjacent to its newly expanded preclinical research ... The solar farm provides a cleaner, renewable energy source ... on the environment. Completion of the Genesis Solar Farm ...
(Date:3/24/2017)... , March 24, 2017 According to a new report ... and Industry Forecast, 2014-2022," the spine bone stimulators market was valued at $562 ... at a CAGR of 3.6% during the forecast period. ... ... Research Logo ...
Breaking Medicine Technology: